Mylan, Bruised by Failed Perrigo Bid, Set for Face-Off on Assets
Mylan NV, bruised by its acrimonious and ultimately unsuccessful bid to buy Perrigo Co., is likely to find itself now competing with the drugmaker for other assets. Both companies may look to buy Impax More...
Mylan’s Hostile Bid For Drug Giant Perrigo Failed
Mylan N.V. (NASDAQ: MYL; TASE) today announced that its offer to acquire all of the issued and to be issued share capital of Perrigo Company plc (NYSE: PRGO; TASE) has lapsed. Perrigo ordinary shares, More...
Mylan’s hostile bid for Ireland-based drugs giant Perrigo likely to fail
If confirmed, the outcome would represent a major victory for Perrigo’s defiant Chief Executive Joseph Papa, and a bitter blow to Mylan’s Executive Chairman Robert Coury, who More...
Mylan-targeted Perrigo held merger talks with Endo -sources
Perrigo Company Plc, the Irish-based generic drugmaker trying to fend off a hostile bid by Mylan NV, held unsuccessful talks to acquire Endo International Plc in an all-stock deal, according More...
Three way takeover battle: Abbott Labs to back Mylan’s acquisition of Perrigo
Abbott Laboratories (NYSE: ABT), said it would back the generic pharmaceutical company Mylan’s (MYL) $34 billion bid acquisition of Perrigo Co Plc (PRGO.N). Abbott Lab potentially helping Mylan forfend More...
Perrigo To Acquires OTC portfolio of drugs from GSK
Irish-Israeli pharmaceutical company Perrigo is continuing its buying spree and does not seem perturbed by the hostile takeover attempts by Mylan NV, which has offered $34 billion in cash and shares for it. Perrigo, More...
Mylan to Teva: stop playing games with our company
Mylan reports that Teva Pharmaceutical Industries, which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake, but did not clarify which anti-trust rule More...
Mylan’s CEO on Teva “They are getting ready to go off the cliff”
“We just don’t think Teva is the right company” to combine with, “They are getting ready to go off the cliff, ” Mylan NV, CEO Heather Bresch said Friday at a conference in New York City hosted More...
Teva Settles Cephalon Case With FTC for $1.2 Billion Over block generic drug competition
Teva Pharmaceutical Industries Ltd. has agreed to pay $1.2 billion in a settlement with the U.S. Federal Trade Commission (FTC), resolving claims that Cephalon Inc. blocked generic drug competition. Teva acquired More...
Three Way Takeover Battle: Mylan mulling improved offer for Perrigo – Bloomberg
Mylan (MYL) is considering an improved offer to shareholders of Perrigo (PRGO) with the aim of acquiring the company and thus heading off the hostile bid for Mylan from Teva Pharmaceutical Industries Ltd. (NYSE: More...